Cytomegalovirus-associated renal allograft rejection: New challenges for antiviral preventive strategies

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 8, 2010, Pages 903-910

  Reischig, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

allograft rejection; CMV; CMV specific T cell immunity; cytomegalovirus; pre emptive antiviral therapy; prophylaxis; renal transplantation; valacyclovir; valganciclovir

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; VALGANCICLOVIR;

CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; GRAFT RECIPIENT; HUMAN; IMMUNOMODULATION; INCIDENCE; KIDNEY ALLOGRAFT REJECTION; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; VIREMIA;

ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955587642     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.63     Document Type: Review

References (60)

1. Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357(25), 2601-2614 (2007).
2. Freeman RB Jr. The indirect effects of cytomegalovirus infection. Am. J. Transplant. 9(11), 2453-2458 (2009).
3. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implication for preventive strategies. J. Clin. Virol. 35(4), 474-477 (2006).
4. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 66(1), 329-337 (2004).
5. Reinke P, Prosch S, Kern F, Volk HD. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transplant. Infect. Dis. 1(3), 157-164 (1999).
6. Kim SJ, Varghese TK, Zhang Z et al. Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter. Am. J. Transplant. 5(7), 1606-1613 (2005).
7. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant. 2(9), 850-856 (2002).
8. Reischig T, Jindra P, Svecova M, Kormunda S, Opatrny K Jr, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J. Clin. Virol. 36(2), 146-151 (2006).
9. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant. 8(1), 69-77 (2008).
10. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant. 6(9), 2134-2143 (2006).
11. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am. J. Transplant. 6(9), 2006-2012 (2006).
12. Potena L, Grigioni F, Ortolani P et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 75(6), 839-843 (2003).
13. Valantine HA, Gao SZ, Menon SG et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis. Circulation 100(1), 61-66 (1999).
14. Potena L, Holweg CT, Chin C et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82(3), 398-405 (2006). (Pubitemid 44223041)
15. Solez K, Colvin RB, Racusec LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am. J. Transplant. 8(4), 753-760 (2008). (Pubitemid 351347767)
16. Helanterä I, Koskinen P, Törnroth T, Loginov R, Grönhagen-Riska C, Lautenschlager I. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation 75(11), 1858-1864 (2003).
17. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 87(3), 436-444 (2009).
18. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant. 8(5), 945-983 (2008).
19. Schnitzler MA, Lowell JA, Hmiel SP et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J. Am. Soc. Nephrol. 14(3), 780-785 (2003).
20. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat. Rev. Immunol. 2(6), 417-426 (2002).
21. Gerna G, Lilleri D, Fornara C et al. Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 6(10), 2356-2364 (2006).
22. Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 9(5), 1214-1222 (2009).
23. Pascher A, Proesch S, Pratschke J et al. Rat cytomegalovirus infection interferes with anti-CD4 mAb-(RIB 5/2) mediated tolerance and induces chronic allograft damage. Am. J. Transplant. 6(9), 2035-2045 (2006).
24. Tu W, Potena L, Stepick-Biek P et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 114(15), 1608-1615 (2006).
25. Nickel P, Bold G, Presber F et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl. Immunol. 20(4), 2038-2042 (2009).
26. Gamadia LE, Remerswaal EB, Suranchno S et al. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. Transplantation 77(12), 1879-1885 (2004).
27. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr. Opin. Infect. Dis. 20(4), 425-431 (2007).
28. Streblow DN, Orloff SL, Nelson JA. Acceleration of allograft failure by cytomegalovirus. Curr. Opin. Immunol. 19(5), 577-582 (2007).
29. Dengler TJ, Raftery MJ, Werle M, Zimmermann R, Schönrich G. Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin-1b. Transplantation 69(6), 1160-1168 (2000).
30. Kloover JS, Soots AP, Krogerus LA et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 69(12), 2641-2647 (2000).
31. Inkinen K, Soots A, Krogerus L, Loginov R, Bruggeman C, Lautenschlager I. Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats. Transplant. Int. 18(6), 743-749 (2005).
32. Lautenschlager I, Soots A, Krogerus A et al. Effects of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation 64(3), 391-398 (1997). (Pubitemid 27349875)
33. Streblow DN, Kreklywich CN, Smith P et al. Rat cytomegalovirus- accelerated transplant vascular sclerosis is reduced with mutation of chemokine-receptor R33. Am. J. Transplant. 5(3), 436-442 (2005).
34. Orloff SL, Streblow DN, Soderberg-Naucler et al. Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants. Transplantation 73(5), 679-688 (2002).
35. Reischig T, Nemcova J, Vanecek T et al. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Antivir. Ther. 15(1), 23-30 (2010).
36. Liapis H, Storch GA, Hill DA, Rueda J, Brennan DC. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue PCR. Nephrol. Dial. Transplant. 18(2), 397-402 (2003).
37. Helanterä I, Koskinen P, Finne P et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl. Int. 19(11), 893-900 (2006).
38. Stassen FR, Vega-Cordova X, Vliegen I, Bruggeman CA. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J. Clin. Virol. 35(3), 349-353 (2006).
39. Compton T, Kurt-Jones EA, Boehme KW et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol. 77(8), 4588-4596 (2003).
40. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143(12), 870-880 (2005).
41. Hodson EM, Jones CA, Webster AC et al. Antiviral medication to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systemic review of randomised controlled trials. Lancet 365(9477), 2105-2115 (2005).
42. Brennan DC, Garlock KA, Singer GG et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64(12), 1843-1846 (1997).
43. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N. Engl. J. Med. 340(19), 1462-1470 (1999). (Pubitemid 29220545)
44. Reischig T, Opatrny K Jr, Bouda M, Treska V, Jindra P, Svecova M. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transplant. Int. 15(12), 615-622 (2002).
45. Reischig T, Jindra P, Mares J et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79(3), 317-324 (2005).
46. Reischig T, Opatrny K Jr, Treska V, Mares J, Jindra P, Svecova M. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Kidney Blood Press. Res. 28(4), 218-225 (2005).
47. Pavlopoulou ID, Syriopoulou VP, Chelioti H et al. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin. Microbiol. Infect. 11(9), 736-743 (2005).
48. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4(4), 611-620 (2004).
49. Künzle N, Petignat C, Francioli et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity. Transplant. Infect. Dis. 2(3), 118-126 (2000).
50. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S78-S86 (2009).
51. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89(7), 779-795 (2010).
52. Miller GG, Kaplan B. Prophylaxis versus preemptive protocols for CMV: do they impact graft survival? Am. J. Transplant. 8(5), 913-914 (2008).
53. Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. 46(6), 840-846 (2008).
54. Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. 10(5), 1228-1237 (2010).
55. Humar A, Paya C, Pescovitz MD et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am. J. Transplant. 4(4), 644-649 (2005).
56. Stern M, Elsasser H, Honger G, Steiger J, Schaub S, Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/ reactivation in kidney transplant recipients. Am. J. Transplant. 8(6), 1312-1317 (2008).
57. Lischka P, Hewlett G, Wunberg T et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54(3), 1290-1297 (2010).
58. Loregian A, Mercorelli B, Muratore G et al. The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 proteins. Agents Chemother. 54(5), 1930-1940 (2010).
59. Grundy JE. Current antiviral therapy fails to prevent the proinflammatory effects of cytomegalovirus infection, whilst rendering infected cells relatively resistant to immune attack. In: Monographs in Virology (Volume 21). Grundy JE Scholz M, Rabenau HF, Doerr HW, Cinatl J Jr (Eds.). Karger, Basel, Switzerland, 67-89 (1998).
60. Goosens VJ, Christiaans MHL, Blok MJ et al. Onset and duration of cytomegalovirus immediate early 1 mRNA expression in the blood of renal transplant recipients. J. Med. Virol. 72(1), 94-101 (2004).